In this paper, Chen and Chhatwal et al show a mathematical simulation model assessing the projected benefits of screening, availability of DAA drugs, diagnostic rate and treatment coverage from the current DAA era to the expected scenario in 2030, the WHO target year for elimination of HCV. The manuscript is novel and relevant in the current era. The authors state in the results that the diagnosis rate would reach between 65-75% and treatment coverage between 65-74% by 2030 in these countries. The number of patients who fail treatment would decrease over time, with the majority of those who fail treatment having been exposed to NS5A inhibitors. However the next line in the conclusion is 'Even in the era of highly effective DAAs, a significant number of patients will remain undiagnosed, untreated, and fail multiple treatments and develop advanced sequelae.' The authors may consider re wording the statement as this is not a direct conclusion from the results and is contradictory. The source data is heterogeneous as it combines multiple sources including published studies, commercial claims data, and simulated clinical practice of HCV in each country. This brings greater emphasis on trial data or those from insurance claims rather than real life experience. The projected HCV incidence rate and the DAA coverage is based on expert opinion only and will vary in region to region and over time.
Please state references for the diagnosis rates. The HCV diagnosis rates varied across countries. In 2014, 122,000 HCV individuals had been diagnosed (diagnosis rate of 59%) in France, 120,000 individuals (55%) in Germany, 531,000 (62%) in Italy, 167,000 (46%) in Spain, and 70,000 (48%) in the UK.
There is 1 main paper table and 12 supplementary tables and a separate set of references for the supplementary data. Again there are 6 figures and 4 supplementary figures, which make the manuscript difficult to process.
This also makes readability difficult as the same reference is quoted twice. Data from the Polaris Observatory is cited as [26] and [10] and the WHO Laboratory as [25] and [15] . Overall the manuscript is of useful interest in the DAA era, and the mathematical model is devised with good predictive ability for the burden of HCV in 2030.
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GENERAL COMMENTS
This is an interesting paper by an eclectic group of authors-most of whom are not located in Europe. The authors acknowledge research funding by Gilead Sciences
The aim of the analysis was to project temporal trends in HCV diagnosis, treatment and disease burden in France, Germany, Italy, Spain and the United Kingdom (UK) using a mathematical simulation model
The bottom line result is that by 2021 the number of individuals cured of HCV would exceed the number of actively infected individuals in the selected countries but that even in the current era of DAA treatments, significant numbers will remain undiagnosed, untreated or will suffer sequelae. Methods The authors rely on published prevalence data; Much of this data is itself modelled and there are many assumptions associated with the extrapolated data. Likewise the POLARIS Observatory data, while comprehensive also utilises a considerable body of extrapolated reasoned data and expert opinion
Have the authors considered extrahepatic deaths as a result of hepatitis C given the considerable body of data?
Drug sales were used as the benchmark for treatment rates. In the early use compassionate use predominated and substantial number of patients were involved in clinical trials and real world programs; are these estimated?
Results: some of the UK data could be updated with the latest publication of Public Health England. (Attached, 2018 report).
The results of all such models are interesting, particularly the time (year) at which the number of cured patients exceeds the remaining viremic patients. The problem with all these models is their validation and the potential weakness of the source data.
The 2030 undiagnosed rate in the various countries remains of concern.
What is the basis for the failed treatment rate: are these related virological factors (genotype, unusual subtypes in immigrant populations, host factors including adherence?)
Is there a calculus for the percentage of patients who will remain untreatable because of the selection of NS3 and NS5A RAS, despite the advent or triple therapy (VOX VEL SOF?)
The authors report a potential increase in incidence. Have they factored in a different pace of the looming opoid epidemic in the countries reviewed?
The prevalence of cirrhosis may be underestimated based on PHE daa.
VERSION 1 -AUTHOR RESPONSE
Review comments from Reviewer 1:
In this paper, Chen and Chhatwal et al show a mathematical simulation model assessing the projected benefits of screening, availability of DAA drugs, diagnostic rate and treatment coverage from the current DAA era to the expected scenario in 2030, the WHO target year for elimination of HCV. The manuscript is novel and relevant in the current era.
Response: We thank Dr. Dhiman for providing constructive comments. Please see our response to each comment below.
The authors state in the results that the diagnosis rate would reach between 65-75% and treatment coverage between 65-74% by 2030 in these countries. The number of patients who fail treatment would decrease over time, with the majority of those who fail treatment having been exposed to NS5A inhibitors.
However the next line in the conclusion is 'Even in the era of highly effective DAAs, a significant number of patients will remain undiagnosed, untreated, and fail multiple treatments and develop advanced sequelae.' The authors may consider re wording the statement as this is not a direct conclusion from the results and is contradictory.
Response: We thank the reviewer for pointing out the confusion in our conclusion statement. Our intention was to highlight the diagnosis rate and treatment coverage by year 2030 are still not sufficiently high to meet the WHO elimination targets (90% diagnosis rate and 80% treatment coverage), and the size (rather than the rate) of the undiagnosed population is still as large as nearly half a million across 5 countries. In response to reviewer's comments, we have now revised our abstract as follows:
(Abstract) "Conclusions: In the era of DAAs, the number of HCV people who achieved cure will exceed the number of viremic patients, but many patients will remain undiagnosed, untreated, fail multiple treatments, and develop advanced sequelae. Scaling-up screening and treatment capacity, and timely and effective retreatment are needed to avail the full benefits of DAAs and to meet HCV elimination targets set by the World Health Organization.
The source data is heterogeneous as it combines multiple sources including published studies, commercial claims data, and simulated clinical practice of HCV in each country. This brings greater emphasis on trial data or those from insurance claims rather than real life experience. The projected HCV incidence rate and the DAA coverage is based on expert opinion only and will vary in region to region and over time.
Response: We agree with the reviewer and acknowledge that our model is parameterized based on data from multiple sources. As typically done in modeling studies, we sought to utilize the best available published data to populate and calibrate our model, and relied on expertise and insights from the domain experts for the parameters that were difficult to estimate from the literature. To address the model input uncertainty, we performed probabilistic sensitivity analysis and additional scenario analysis to assess the effects of key model parameters and assumptions on the model outcomes and findings (see details in Supplement S2).
The role of generic DAAs in the treatment of HCV as a cost-effective strategy should be mentioned.
Response: As suggested, we have now included the below sentence in the Discussion:
(Page 17, paragraph 1) "… not merely cost-effective but cost-saving [5, 6] . Making low-price authorized generic DAAs available could further help in reducing barriers to scaling-up treatment uptake and to achieve greater cost-savings [1, 2] . Therefore, … "
The assumptions on prior treatment failure with PEGIFN/RBV and DAAs (either SOF/RBV or NS5A experience) need a reference.
Response: We made the assumptions on prior treatment failures and the limits of maximum number of treatment based on expert opinion. Our rationale is as follows: Since PEG-RBV regimen has low SVR rates and is associated with substantial side effects, we assumed that patients would not have more than 2 treatment attempts; we assumed patients to receive first-generation PIs for at most once because the regimen was available only during a short period of time (2012) (2013) ; for DAAs, considering the high SVR rates (>90%) and minimal side effects, there are no major clinical concerns that prevent patients from receiving retreatment after previous treatment failures, and patients could would be very likely to be cured within 3 treatment attempts.
Response: We clarify that the above diagnosis rates are the outcomes of our model (and not inputs), as such rates are not available in literature. We provided the details of modeling the HCV awareness and diagnosis rates in Supplement page 7 (Table S9) , and included the uncertainty results for diagnosis rate outcomes from probabilistic sensitivity analysis in Supplement S3 Table S14 .
There is 1 main paper Response: We acknowledge that our model is comprehensive (and complex), and it is challenging to present all modeling details (disease dynamics, HCV treatment and diagnosis, country-specific settings, etc.) in the main text. Therefore, for model transparency, we included the necessary details of modeling in the appendix.
We thank the reviewers for pointing out the duplicated references. We have now updated the references of both main text and appendix. We kept two separate references for main text and appendix to be self-containing.
Overall the manuscript is of useful interest in the DAA era, and the mathematical model is devised with good predictive ability for the burden of HCV in 2030.
Reviewer comments from Reviewer 2
The bottom line result is that by 2021 the number of individuals cured of HCV would exceed the number of actively infected individuals in the selected countries but that even in the current era of DAA treatments, significant numbers will remain undiagnosed, untreated or will suffer sequelae.
Response: We thank Dr. Dusheiko for providing a detailed review and positive feedback on our manuscript. Please see our point-by-point responses below, which we hope have addressed the raised concerns.
Methods
The authors rely on published prevalence data; Much of this data is itself modelled and there are many assumptions associated with the extrapolated data. Likewise the POLARIS Observatory data, while comprehensive also utilises a considerable body of extrapolated reasoned data and expert opinion Response: We agree with the reviewer and acknowledge that we had to rely on appropriate assumption where data lack. We used the best available evidence to validate our model with known outcomes, which provides some reassurance that our assumptions are valid. We further conducted extensive sensitivity analysis to test the robustness of our model's parameters/assumption on outcomes/conclusions. In addition to matching the trajectory of model-predicted HCV prevalence with the Polaris Observatory (Supplement S1, Figure S1 ), we now included additional validation results (see below table) comparing the natural history of HCV compared with data from a large observational study in Supplement S1 Table S8 , which further showed that our model is well in line with empirical observations.
Model results
Reference/target values Achieved SVR Failed to achieve SVR Achieved SVR Failed to achieve SVR DC 2.6%-3.2% 26.1%-50.1% 2.1% (0-4.5%) 29.9% (24.3%-35.5%) HCC 2.2%-2.8% 17%-35.8% 5.1% (1.3%-8.9%) 21.8% (16.6%-27.0%) LRD or LT 0.3%-0.7% 3.3%-10.6% 1.9% (0-4.1) 27.4% (22.0%-32.8%)
We have also revised the text in the Method section, which reads as follows:
(Page 8, paragraph 2) "We cross-validated the natural history results of our model by comparing model-predicted 10-year cumulative incidence of advanced sequelae in cirrhotic patients with that reported by an observational study [3] (Table S8 )."
For projection of future outcomes, we made assumptions on the future trends of certain parameters including HCV incidences, screening and treatment rates, which we acknowledge will be subject to uncertainty. As suggested in the reviewer's following comments, we evaluated the model in several additional scenarios to assess the potential impact of these assumptions on model outcomes and findings. We now included these additional sensitivity analyses in Supplement S2 and Supplement S3 Table S14 .
Response: We did not consider extrahepatic mortality benefits from treatment in our model because of limited data. We agree with the reviewer on an increasing evidence in the literature about extrahepatic manifestations due to chronic hepatitis C infection, but such data, (e.g., review article [4] and a meta-analysis [5]), to our knowledge, are related to incidence, prevalence, and cost, but not mortality, of extrahepatic conditions (e.g., diabetes, cardiovascular disease, lymphoma, and so on). It is plausible to deduce that HCV cure could reduce the incidence of the extrahepatic conditions, and further reduce the mortality from the extrahepatic conditions, but we felt that estimating the effects on the mortality by capturing the underlying mechanism for all extrahepatic conditions is beyond the scope of this modeling study. Therefore, without direct estimates for extrahepatic mortality from the literature, we did not explicitly consider this outcome in our model, and discussed it in our model limitations.
(Page 18, Paragraph 2) "Second, we did not consider the potential benefits of HCV treatment on reduction in extrahepatic mortality because of limited data." Drug sales were used as the benchmark for treatment rates. In the early use compassionate use predominated and substantial number of patients were involved in clinical trials and real world programs; are these estimated?
Response: We thank the reviewer for this question. We did not explicitly include such treated cases in our original treatment capacity estimates. Based on the expert's opinions (from our team), the number of patients who receive treatment through compassionate use and clinical trials would be approximately 1-2% of the total patient population. To account for such estimates, we optimistically assumed that the annual treatment uptake will be 5% higher than our previously assumed values and updated the annual treatment uptake (see details in Supplement S2 and results in Supplement S3 Table S14 ). We found that such changes would yield minimal differences to the overall model outcomes and our main findings.
Response: We thank Dr. Dusheiko for bringing this relevant publication of Public Health England to our attention. We compared our model's relevant inputs/outputs with the report and summarized our findings below. This additional validation source further enhances our confidence in the model outcomes.
For treatment-specific data from this report, we used the following data as additional validation points:
 Treatment capacity during 2007-2017: Because the estimates from this report (Figure 8 in this report) is for England [6] , our estimates are expected to be higher. In addition, we identified a UK-specific report on HCV [7] , and the numbers of treatment during 2007-2017 closely match the provisional estimates from this UK-based report (see below figure) . We have now included it in Supplement S1.
 Number of diagnosis in each year: The reported numbers in Figure 3 of the England report [6] represent the diagnosis year for treated patients in the Hepatitis C patient registry, which do not necessarily represent the number of all diagnosis in the country for each year. Therefore, we do not use this data.
 An SVR12 of 95.2% was reported [6] with majority of the treatment being DAAs, which is also in line with the SVR rates used in our model (Supplement S1, Table S11 ).
 The England report [6] showed that around one third (32%) had cirrhosis prior to treatment. Our model also showed 30%-40% patients receiving treatment are cirrhotic during 2014-2016.
